Clinical observation of bevacizumab combined with paclitaxel and carboplatin chemotherapy in the treatment of persistent or recurrent cervical cancer

ZHANG Liyi; JIANG Fengxi; GUI Dingqing

doi:10.6039/j.issn.1001-0408.2024.17.12

您当前的位置：

首页 >

文章列表页 >

Clinical observation of bevacizumab combined with paclitaxel and carboplatin chemotherapy in the treatment of persistent or recurrent cervical cancer

更新时间：2024-09-09

- Clinical observation of bevacizumab combined with paclitaxel and carboplatin chemotherapy in the treatment of persistent or recurrent cervical cancer
- ZHONGGUO YAOFANG Vol. 35, Issue 17, Pages: 2126-2130(2024)
- 作者机构：
  
  达州市中心医院妇产科，四川达州　635000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.17.12
  CLC： R969.4;R979.1
- Published：15 September 2024，
  
  Received：20 April 2024，
  
  Revised：19 August 2024，
- 稿件说明：
移动端阅览
张力忆,蒋奉希,桂定清.贝伐珠单抗联合紫杉醇+卡铂治疗持续性或复发性宫颈癌的临床观察 ^Δ[J].中国药房,2024,35(17):2126-2130.

ZHANG Liyi,JIANG Fengxi,GUI Dingqing.Clinical observation of bevacizumab combined with paclitaxel and carboplatin chemotherapy in the treatment of persistent or recurrent cervical cancer[J].ZHONGGUO YAOFANG,2024,35(17):2126-2130.
张力忆,蒋奉希,桂定清.贝伐珠单抗联合紫杉醇+卡铂治疗持续性或复发性宫颈癌的临床观察 ^Δ[J].中国药房,2024,35(17):2126-2130. DOI： 10.6039/j.issn.1001-0408.2024.17.12.

ZHANG Liyi,JIANG Fengxi,GUI Dingqing.Clinical observation of bevacizumab combined with paclitaxel and carboplatin chemotherapy in the treatment of persistent or recurrent cervical cancer[J].ZHONGGUO YAOFANG,2024,35(17):2126-2130. DOI： 10.6039/j.issn.1001-0408.2024.17.12.

摘要

目的

探讨贝伐珠单抗联合紫杉醇（PTX）+卡铂（CBP）化疗方案治疗持续性或复发性宫颈癌的近远期疗效，以及对患者生存质量、肿瘤标志物和安全性的影响。

方法

采用随机数字表法将我院2020年1月－2022年10月收治的持续性或复发性宫颈癌患者80例分为对照组（40例）与观察组（40例）。两组患者均接受PTX+CBP化疗，观察组患者同时联用贝伐珠单抗治疗，均连续治疗6个周期。比较两组患者的近期疗效、毒副反应发生情况以及治疗前和全部疗程结束时的欧洲癌症研究与治疗组织生活质量核心问卷量表30（EORTC QLQ-C30）评分、血清肿瘤标志物[癌胚抗原（CEA）、糖类抗原125（CA125）、鳞状细胞癌抗原（SCCA）]水平。采用Kaplan-Meier法绘制两组患者的生存曲线并通过Log-rank检验比较两组患者的无进展生存期（PFS）和总生存期（OS）。

结果

观察组患者的客观有效率显著高于对照组（62.50% vs. 35.00%，

＜0.05），中位PFS（9.30个月 vs. 6.30个月）和中位OS（14.90个月 vs. 10.60个月）均显著长于对照组（

＜0.05），治疗后的EORTC QLQ-C30评分显著高于对照组（

＜0.05）。相较于治疗前，两组患者治疗后的血清CEA、CA125和SCCA水平均显著降低（

＜0.05），且观察组患者较对照组的降低幅度更大（

＜0.05）。两组患者治疗期间各类型毒副反应分级比较，差异无统计学意义（

＞0.05）；多数患者的毒副反应在停药后1～2个月自动消失或在对症治疗后消失。

结论

贝伐珠单抗联合PTX+CBP化疗方案可有效提高持续性或复发性宫颈癌患者的客观有效率，降低血清肿瘤标志物水平，提升患者生存质量，延长患者生存期，且安全性良好。

Abstract

OBJECTIVE

To explore the short-term and long-term efficacy of bevacizumab combined with paclitaxel （PTX） and carboplatin （CBP） chemotherapy in the treatment of persistent or recurrent cervical cancer， as well as its impact on patient quality of life， tumor markers and safety.

METHODS

Totally 80 patients with persistent or recurrent cervical cancer admitted to our hospital from January 2020 to October 2022 were randomly divided into control group （40 cases） and observation group （40 cases） using a random number table method. Both groups received PTX+CBP chemotherapy， while the observation group was treated with bevacizumab in combination. Both groups were treated continuously for 6 cycles

. The recent efficacy， the incidence of toxic side effects as well as European Organization for Research and Treatment of Cancer Life Questionnaire Core 30 （EORTC QLQ-C30） scores， and the serum tumor markers [carcinoembryonic antigen （CEA）， carbohydrate antigen 125 （CA125）， and squamous cell carcinoma antigen （SCCA）

]

levels before and at the end of the entire course of treatment were compared between two groups. The survival curves of the two groups were drawn by using Kaplan-Meier method， and progression-free survival （PFS） and overall survival （OS） were compared between the two groups by

Log-rank test.

RESULTS

The objective response rate of the observation group was significantly higher than that of the control group （62.50% vs. 35.00%，

＜0.05）， and the median PFS （9.30 months vs. 6.30 months） and median OS （14.90 months vs. 10.60 months） were also significantly longer than the control group （

＜0.05）. EORTC QLQ-C30 score of the observation group after treatment was significantly higher than that of the control group （

＜0.05）. Compared to before treatment， the serum levels of CEA， CA125 and SCCA in both groups were significantly reduced after treatment （

＜0.05）， while the observation group had a larger decrease （

＜0.05）. There was no significant difference in the grading of various types of toxic side effects between the two groups during treatment （

＞0.05）. Most patients experienced automatic disappearance of toxic side effects 1-2 months after discontinuation of medication， or symptoms disappearance after symptomatic treatment.

CONCLUSIONS

The combination of bevacizumab and PTX+CBP chemotherapy regimen can effectively improve the objective efficacy rate of persistent or recurrent cervical cancer， reduce serum tumor marker levels， improve patient quality of life， prolong survival， and have good safety.

关键词

持续性宫颈癌复发性宫颈癌贝伐珠单抗紫杉醇卡铂临床疗效生存质量肿瘤标志物安全性

Keywords

recurrent cervical cancerbevacizumabpaclitaxelcarboplatintherapeutic efficacyquality of lifetumor markerssafety

references

李道娟，师金，靳晶，等. 宫颈癌的流行病学趋势[J]. 中华肿瘤杂志，2021，43（9）：912-916.

LI D J，SHI J，JIN J，et al. Epidemiological trend of cervical cancer[J]. Chin J Oncol，2021，43（9）：912-916.

VASHISHT S，MISHRA H，MISHRA P K，et al. Structure，genome，infection cycle and clinical manifestations associated with human papillomavirus[J]. Curr Pharm Biotechnol，2019，20（15）：1260-1280.

程蕾，陈周红. 紫杉醇在治疗晚期或复发性宫颈癌中的应用分析[J]. 基因组学与应用生物学，2020，39（1）：337-342.

CHENG L，CHEN Z H. Analysis of paclitaxel in the treatment of advanced or recurrent cervical cancer[J]. Genom Appl Biol，2020，39（1）：337-342.

LIONTOS M，KYRIAZOGLOU A，DIMITRIADIS I，et al. Systemic therapy in cervical cancer：30 years in review[J]. Crit Rev Oncol Hematol，2019，137：9-17.

KOTAKA S，KONDO E，KAWAI Y，et al. Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer[J]. J Gynecol Oncol，2023，34（5）：e60.

FAZEL F，MALEKAHMADI M，FEIZI A，et al. Suprachoroidal injection of triamcinolone acetonide plus intravitreal bevacizumab in diabetic macular edema：a rando- mized pilot trial[J]. BMC Ophthalmol，2023，23（1）：40.

吴兴，李婵娟，丁伯福，等. 两均数比较的优效性临床试验样本量估计[J]. 数理医药学杂志，2013，26（5）：517-519.

WU X，LI C J，DING B F，et al. Sample size estimation in superiority clinical trials for two means comparison[J]. J Math Med，2013，26（5）：517-519.

EISENHAUER E A，THERASSE P，BOGAERTS J，et al. New response evaluation criteria in solid tumours：revised RECIST guideline：version 1.1[J]. Eur J Cancer，2009，45（2）：228-247.

AARONSON N K，AHMEDZAI S，BERGMAN B，et al. The European Organization for Research and Treatment of Cancer QLQ-C30：a quality-of-life instrument for use in international clinical trials in oncology[J]. J Natl Cancer Inst，1993，85（5）：365-376.

皋文君，刘砚燕，袁长蓉. 国际肿瘤化疗药物不良反应评价系统：通用不良反应术语标准4.0版[J]. 肿瘤，2012，32（2）：142-144.

GAO W J，LIU Y Y，YUAN C R. International evaluation system for adverse events of chemotherapeutic drugs in cancer treatment：CTCAE v4.0[J]. China Cancer，2012，32（2）：142-144.

周晖，刘昀昀，罗铭，等. 《2020NCCN子宫颈癌临床实践指南（第1版）》解读[J]. 中国实用妇科与产科杂志，2020，36（2）：131-138.

ZHOU H，LIU Y Y，LUO M，et al. Interpretation of 2020 NCCN Clinical Practice Guidelines for Cervical Cancer （1st Edition）[J]. Chin J Pract Gynecol Obstet，2020，36（2）：131-138.

MARTINO G D，LISSONI A A，FERRARI D，et al. Dose-dense neoadjuvant chemotherapy with paclitaxel and carboplatin in cervical cancer：efficacy on pathological response[J]. Anticancer Res，2021，41（1）：497-502.

张小娜，符燕妹，田燕，等. 老年妇科肿瘤患者紫杉醇联合卡铂化疗后CINV发生影响因素[J]. 中国老年学杂志，2023，43（6）：1316-1319.

ZHANG X N，FU Y M，TIAN Y，et al. Influencing factors of CINV after paclitaxel combined with carboplatin chemotherapy in elderly patients with gynecological tumors[J]. Chin J Gerontol，2023，43（6）：1316-1319.

CHUAI Y H，RIZZUTO I，ZHANG X，et al. Vascular endothelial growth factor （VEGF） targeting therapy for persistent，recurrent，or metastatic cervical cancer[J]. Cochrane Database Syst Rev，2021，3（3）：CD013348.

王君，刘月合，王春佟. 顺铂+紫杉醇化疗联合贝伐珠单抗治疗复发性宫颈癌的疗效观察[J]. 医学临床研究，2019，36（3）：541-543.

WANG J，LIU Y H，WANG C T. Clinical observation of cisplatin plus paclitaxel combined with bevacizumab in the treatment of recurrent cervical cancer[J]. J Clin Res，2019，36（3）：541-543.

王利君，赵虎，袁博，等. 贝伐珠单抗联合紫杉醇和铂类化疗对晚期转移性宫颈癌的疗效及对T淋巴细胞亚群和肿瘤标志物的影响[J]. 肿瘤防治研究，2023，50（10）：994-998.

WANG L J，ZHAO H，YUAN B，et al. Efficacy of bevacizumab combined with paclitaxel and platinum-based chemotherapy in advanced metastatic cervical cancer and its effect on T lymphocyte subsets and tumor markers[J]. Cancer Res Prev Treat，2023，50（10）：994-998.

张瑜. 血清SCCA、CEA、CA125、CA19-9联合检测在宫颈癌与癌前病变鉴别诊断中的应用价值[J]. 标记免疫分析与临床，2019，5（4）：675-678，682.

ZHANG Y. The application value of combined detection of serum SCCA，CEA，CA125 and CA19-9 in the differential diagnosis of cervical cancer and precancerous lesions[J]. Labeled Immunoass Clin Med，2019，5（4）：675-678，682.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy and safety of amphotericin B combined with posaconazole in the treatment of cryptococcal meningitis complicated with AIDS

Clinical observation of camrelizumab combined with pemetrexed and nedaplatin in the treatment of EGFR/ALK wild-type advanced non-squamous non-small cell lung cancer

Clinical observation of venetoclax combined with homoharringtonine and cytarabine in the treatment of acute myeloid leukemia

Clinical observation of goserelin combined with estradiol valerate in the treatment of endometriosis in patients of childbearing age after laparoscopic surgery

Real-world study on piperacillin-tazobactam in the treatment of complicated urinary tract infection in adults

Related Author

ZHANG Lu

LU Yanqiu

LIU Dan

HU Jing

TAN Fengyan

TANG Yiding

MENG Long

SONG Jie

Related Institution

Dept. of Pharmacy， the First Affiliated Hospital of Army Medical University

Dept. of Infection， Chongqing Public Health Medical Center

Dept. of Clinical Pharmacy， Zhongjiang County People’s Hospital

School of Pharmacy， Chongqing Medical University

Dept. of Pharmacy， the First Affiliated Hospital of Chongqing Medical University

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰